000			01971 a2200577 4500
005			20250517032906.0
264		0	_c20160512
008			201605s 0 0 eng d
022			_a1573-0646
024	7		_a10.1007/s10637-015-0252-4 _2doi
040			_aNLM _beng _cNLM
100	1		_aEigl, B J
245	0	0	_aA phase II study of the HDAC inhibitor SB939 in patients with castration resistant prostate cancer: NCIC clinical trials group study IND195. _h[electronic resource]
260			_bInvestigational new drugs _cAug 2015
300			_a969-76 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
650	0	4	_aAged
650	0	4	_aAged, 80 and over
650	0	4	_aAntineoplastic Agents _xadverse effects
650	0	4	_aBenzimidazoles _xadverse effects
650	0	4	_aDisease-Free Survival
650	0	4	_aHistone Deacetylase Inhibitors _xadverse effects
650	0	4	_aHumans
650	0	4	_aKallikreins
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aNeoplastic Cells, Circulating _xmetabolism
650	0	4	_aPTEN Phosphohydrolase _xgenetics
650	0	4	_aProstate-Specific Antigen
650	0	4	_aProstatic Neoplasms, Castration-Resistant _xblood
650	0	4	_aSerine Endopeptidases _xgenetics
650	0	4	_aTrans-Activators _xgenetics
650	0	4	_aTranscriptional Regulator ERG
700	1		_aNorth, S
700	1		_aWinquist, E
700	1		_aFinch, D
700	1		_aWood, L
700	1		_aSridhar, S S
700	1		_aPowers, J
700	1		_aGood, J
700	1		_aSharma, M
700	1		_aSquire, J A
700	1		_aBazov, J
700	1		_aJamaspishvili, T
700	1		_aCox, M E
700	1		_aBradbury, P A
700	1		_aEisenhauer, E A
700	1		_aChi, K N
773	0		_tInvestigational new drugs _gvol. 33 _gno. 4 _gp. 969-76
856	4	0	_uhttps://doi.org/10.1007/s10637-015-0252-4 _zAvailable from publisher's website
999			_c24909382 _d24909382